Information

01.04.2025

Expansion of the Swissmedic position paper on real world evidence

Swissmedic is expanding its position paper on real world evidence (RWE) with an overview of relevant international guidelines and publications

01.04.2025

Changes to the Guidance document Meetings for applicants for authorisation procedures

Optimisation of meetings for applicants for authorisation procedures

01.04.2025

Changes to the Guidance documents Fast-track authorisation procedure and Temporary authorisation for human medicinal products

Clarification of the submission date for an authorisation application for a fast-track authorisation procedure (FTP) or the implementation of temporary authorisation (temp.auth./temp.AI)

17.03.2025

Newly appointed Swissmedic Expert Committees start work

The Swissmedic Medicines Expert Committees (SMEC) have begun the 2025–2028 period of office with a new line-up

07.03.2025

Overview of international authorisation procedures

International collaboration in authorisation procedures

28.02.2025

Authorisations of human medicinal products with a new active substance and additional indications 2024

46 human medicinal products with new active substances authorised

01.01.2025

Optimisation of labelling phase for human medicinal products

Swissmedic is optimising the labelling phase: text review letters should be avoided where possible and the Swissmedic time limits are being shortened

01.01.2025

Changes to the form Information for application Art. 13 TPA

The previous form Information for application Art. 13 TPA has been divided into two forms: one specifically for veterinary medicinal products and the other for human medicinal products

01.01.2025

Election of the members of the Swissmedic Medicines Expert Committees

Election and re-election of our external experts for the new period of office 2025–2028

01.01.2025

Changes to the Guidance document Import of a human medicinal product according to Art. 14 para. 2 and 3 TPA (parallel import)

Market surveillance measures based on safety signals or quality defects in the original medicinal product must also be implemented for parallel imported medicinal products

01.01.2025

Amendment of the rules of the Swissmedic Medicines Expert Committees

Maximum number of ordinary VMEC members increased from seven to nine

01.01.2025

Changes to the Full declaration form

Listing the full qualitative composition of aromatic substances in human and veterinary medicinal products is no longer mandatory

15.10.2024

Changes to the guidance documents Fast-track authorisation procedure and Temporary authorisation for human medicinal products

Optimisation of the application procedure for the implementation of a fast-track authorisation procedure and the implementation of temporary authorisation